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Abstract
Multivariate meta-analysis is increasingly utilized in biomedical research to combine data of
multiple comparative clinical studies for evaluating drug efficacy and safety profile. When the
probability of the event of interest is rare or when the individual study sample sizes are small, a
substantial proportion of studies may not have any event of interest. Conventional meta-analysis
methods either exclude such studies or include them through ad-hoc continuality correction by
adding an arbitrary positive value to each cell of the corresponding 2 by 2 tables, which may result
in less accurate conclusions. Furthermore, different continuity corrections may result in
inconsistent conclusions. In this article, we discuss a bivariate Beta-binomial model derived from
Sarmanov family of bivariate distributions and a bivariate generalized linear mixed effects model
for binary clustered data to make valid inferences. These bivariate random effects models use all
available data without ad hoc continuity corrections, and accounts for the potential correlation
between treatment (or exposure) and control groups within studies naturally. We then utilize the
bivariate random effects models to reanalyze two recent meta-analysis data sets.
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1. Introduction
The growth of evidence-based medicine has led to an increase in attention to meta-analysis.1
Meta-analysis, also known as systematic overview, is a statistical process commonly used in
biomedical research of combining the information from several independent studies
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the aim of being able to resolve contradictory issues that cannot be concluded from a single
study alone.
In meta-analysis of a set of N clinical trials with a binary outcome comparing an
experimental treatment with a placebo, data can be represented as a series of 2 by 2 tables.
The standard fixed and random meta-analysis methods for providing an overall estimate of
the treatment effect across all studies rely on some assumptions.2 Specifically, the fixed
effect model assumes homogeneous treatment effects across all studies. Let θi be the value
of a chosen measure (e.g., risk difference or log relative risk) of treatment effect in the ith
study (i = 1, 2, …, N), the homogeneity requires θi = θ (i = 1, 2, …, N). Let θ̂i be an
estimate of θi, and wi denote the weight, which is often taken to be the reciprocal of the
estimated variance ν̂i of θ̂i (i.e., ŵi = 1/ν̂i),3 then the overall treatment effect based on the
fixed effect model is estimated as a weighted average of the individual study estimated
treatment effects, that is, . Under the combined null hypothesis H0: θi = 0
(i = 1, 2, …, N), the test statistic  follows a χ2 distribution with 1 degree
of freedom. A formal test of homogeneity can be performed using the Cochran’s Q statistic,
defined by , which has approximately a  distribution under the null
hypothesis H0: θi= θ (i = 1, 2, …, N).
Through a random-effects model, DerSimonian and Laird4 provided a way of incorporating
heterogeneity into the overall estimate by including a between-study variance component
. It basically assumes that θ̂i ~ N (θi, v̂i) and .2 The overall treatment effect is
once again obtained as a weighted average with the weight being estimated as
, i.e., . Under the combined null hypothesis H0: θi = 0 (i =
1, 2, …, N), the test statistic  follows a χ2 distribution with 1 degree of
freedom. The method of moments estimate of  is given by
.4
A concern on these conventional two-step meta-analysis methods is that they require
estimating study- specific treatment effect θ̂i (commonly expressed by log relative risk, log
odds ratio or risk difference) and its variance ν̂i based on the normal approximation. When
the probability of the event of interest is rare or if the individual study sample sizes are
small, this normality assumption might not hold. Furthermore, a substantial proportion of
studies may not have any event of interest. To circumvent the issues of zero cells, the
conventional meta-analysis methods either exclude such studies5 or add an arbitrary positive
value to each cell of the corresponding 2 by 2 tables in the analysis, which may lead to less
accurate conclusions. For example, different continuity corrections may result in different
conclusions.6 An interesting yet challenging methodology question is how to use all
available data without assigning an arbitrary number to the empty cells in meta-analysis.7–10
Furthermore, it has been noted that these weighting-according-to-the-variance methods may
introduce biases in meta-analyses of binary outcomes because this weighting scheme favors
studies with certain frequencies of outcome events.11 The relative weights for the individual
studies in a meta-analysis may change considerably among different choices of effect
measurements, which may lead to contradictory conclusions. This is particularly true for the
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sparse data scenario. Specifically, a study with zero event in both treatment and placebo
groups, which would be excluded on a relative scale, would be included and even be given a
large weight on a risk difference scale.6
Recently, multivariate random effects models for meta-analyses have become increasingly
popular in biomedical research. For example, multivariate random effects models have been
proposed for meta-analyses of diagnostic test studies12–18 and correlated multiple
outcomes.19, 20 Given the potential issues of applying conventional meta-analysis methods
based on a univariate outcome, we discuss bivariate random effects models to deal with
those challenges for meta-analyses of comparative clinical trials with binary outcomes in
this article. Although the proposed methods were primarily presented for bivariate meta-
analyses, they can be easily generalized to multivariate meta-analyses. Specifically, Section
2 shows the estimation of marginal treatment effects using the maximum likelihood methods
under two models, i.e., a generalized linear mixed effects model and a bivariate Beta-
binomial model. In Section 3, we reanalyze the data from two case studies: the study of type
2 diabetes mellitus after gestational diabetes 21 and the study of myocardial infarction with
Rosiglitazone.5 Section 4 concludes this article with a brief discussion.
2. Bivariate Random Effects Models for Meta-Analysis of Comparative
Studies
Let nki be the number of subjects, and pki be the probability of “success” for the ith study (i
= 1, 2, …, N) in the kth treatment (or exposure) group with k = 1 denoting the placebo (or
unexposed) group and k =2 denoting the treated (or exposed) group. Let Ykij denote a
Bernoulli random variable with value 1 denoting a “success” and value 0 denoting a
“failure” for the jth subject (j = 1, 2, …, n) of the ith study in the kth treatment group. Let
 be the total number of “success” in the kth treatment group in the ith study. In the
first stage, conditional on the probability of events (i.e., pki) and the number of subjects (i.e.,
nki) of the kth treatment group in the ith study, the bivariate random effects model assumes
that Xki is independently binomially distributed as Bin (nki, pki) for k = 1, 2 and i = 1, 2, …,
N, that is,
(1)
In the second stage, the joint distribution f(p1i, p2i), which is also denoted as f(p1, p2) for
ease of notation, is specified. Specifically, we first review the bivariate generalized linear
mixed effects models and then propose the bivariate Beta-binomial models as an alternative,
for the evaluation of marginal treatment or exposure effect. Note that bivariate models are
commonly used when there are two outcomes (e.g. the response to a treatment and the
appearance of a side effect), in this article, we use bivariate models to jointly model the
study-specific response rates in the placebo group and the treatment group in a meta-analysis
with multiple studies.
2.1 Bivariate Generalized Linear Mixed Effects Models
In the second stage, the bivariate generalized linear mixed effects model (BGLMM) assumes
a bivariate normal distribution of (p1i, p2i) in a transformed scale, which implies a linear
relationship between p1i and p2i on a transformed scale. It is generally specified as follows,
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where g() is the link function such as the commonly used logit, probit and complementary
log-log transformation functions, (ν1,ν2) are the fixed effects, and 
is the variance-covariance matrix. To implement the natural constraint of −1≤ρ≤1, one can
use the Fisher’s z transformation as ρ= [exp (2z) − 1]/[exp(2z)+1].
Based on the model in equation (2), the median success probability in the kth treatment
group for the population can be estimated as M(pk)= g−1 (νk), k =1, 2. And, its mean can be
estimated as
(3)
where φ() is the standard Gaussian density function. Based on the bivariate normality
assumption of (ν1i, ν2i)T, the expected success probability in group k (k = 1, 2) at a given
success probability in group l (l = 1, 2) in the transformed scale is given by
(4)
Thus, the BGLMM implies a linear relationship between p1 and p2 on a transformed scale.
2.2 Bivariate Beta-Binomial Models
As an alternative, beta-binomial distributions can be used to model the success probabilities
of the treatment and control groups to account for the within-study correlation. To allow for
the possible correlation between the success probabilities in the treatment and control
groups, Lee22 introduced a class of bivariate Beta-binomial distributions using the
framework introduced by Sarmanov.23 Such bivariate Beta-binomial distributions can be
used to model the success probabilities of (p1i, p2i) jointly as follows,
(5)
where αk, βk > 0,  and . The bivariate beta-
binomial distribution specified by equation (5) has several attractive features. First, the
marginal distribution of pk follows a Beta distribution f(pk)= Beta(αk, βk). Secondly, a
correlation between the success probabilities in the treatment and control groups is allowed
and modeled by ρ= ωδ1δ2, where  is the variance of pk. When ω =
0, equation (5) collapses to the product of two univariate Beta densities, corresponding to
independent Beta distributions for p1 and p2. To ensure a valid joint probability density
function, ω must satisfy the condition
(6)
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To ensure a valid joint probability density function for (p1, p2) and avoid computational
difficulties, we re-parameterize ω by the unconstrained parameter η as follows,
(7)
The conditional distribution of pk for a chosen pl is
. Thus, the conditional
mean of pk for a chosen pl is given by E(pk | pl) = μk + ρδk/δl(pl − μl), and the conditional
variance of pk for a chosen pl is given by
(8)
Thus, the bivariate Beta-Binomial model implies a linear relationship between p1 and p2 on
the original scale. The unconditional joint probability density function for (X1= x1i, X2= x2i)
is,
(9)
which leads to the following log-likelihood function for the observed 2 × 2 tables after
ignoring some constant,
(10)
where ω must satisfy the condition in equation (6) to ensure nonnegative probability.
2.3 Marginal Treatment Effects: Risk Difference and Risk Ratio
Although the issue of deciding which effect measure to use in a particular application is non-
trivial,1 we focus on the estimation of risk ratio (RR) and risk difference (RD) here for two
reasons: 1) the interpretation of odds ratio (OR) as an estimate of RR often leads to
exaggerated associations when the binary outcome of interest is common;24–26 and 2) the
well-known non-collapsibility issue related to OR makes it undesirable in interpretation and
estimation.27, 28 For example, in the presence of effect modification, when an exposure
increases risk but all risks are less than 0.5, it is possible for the relative risk and the risk
difference to change in the same direction, but the odds ratio to change in the opposite
direction.29 In this article, we focus on the overall marginal (or population averaged)
treatment (or exposure) effect, as suggested by McCullagh,30, 31 which is defined as the risk
difference (RD) = E(p1) − E(p2) and the risk ratio (RR) = E(p1)/E(p2), where
 for the BGLMM and E(pk) = αk/(αk + βk) for the
bivariate Beta-binomial model, k =1,2. Furthermore, although the computation of E(pk)(k =
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1,2) from BGLMM involves integration, there is a closed-form formula of
 (k= 1,2) for the bivariate probit random effects model, and a well-
established approximation formula of  (k= 1,2) for the bivariate
logit random effects models,32 where . For the complementary log-log
random effects models, E(pk) can be easily computed by numerical integration, for example,
by the trapezoidal rule with 1,000 equal space subintervals as implemented in this article.
2.4 Model Implementation
The bivariate Beta-binomial model and the bivariate generalized linear mixed model can be
fitted using commonly used statistical software. We implement it through the SAS
NLMIXED procedure (SAS Institute Inc., Cary, NC), which maximizes the likelihood
function by dual quasi-Newton optimization techniques for the bivariate Beta-binomial
model, and uses an adaptive Gaussian quadrature to approximate the likelihood integrated
over the random effects for BGLMM.33 Furthermore, the delta method built in SAS
NLMIXED is used to compute the population averaged overall treatment effect estimates
and their standard errors based on the normal approximation. To select a model that can give
a better goodness of fit, either the finite sample corrected Akaike’s Information Criterion
(AICC) or the Bayesian Information Criterion (BIC) can be used as the guideline.34
3. Two Case Studies
To illustrate and compare the performance of the bivariate Beta-binomial model and the
bivariate generalized linear mixed effects models discussed in this article, we apply them to
two recently published meta-analyses.
3.1 Example 1: Meta-analysis of type 2 diabetes mellitus after gestational diabetes
Recently, Bellamy et al.21 presented an interesting comprehensive systematic review and
meta-analysis to assess the strength of association between gestational diabetes and type 2
diabetes mellitus. In summary, 20 cohort studies were included in the meta-analysis with
675,455 women and 10,859 type 2 diabetic events. Table 1 shows the frequencies of the
diabetic events for these 20 studies.
We fitted the bivariate Beta-binomial and the bivariate generalized linear mixed effects
models as described in Section 2 to study the association between gestational diabetes and
type 2 diabetes mellitus. Table 2 presents the parameter estimates and their standard errors,
including the population averaged risk of type 2 diabetes mellitus for those with and without
gestational diabetes, population averaged risk difference and risk ratio, and the goodness of
fit measures including the finite sample corrected Akaike’s Information Criterion (AICC)
and the Bayesian Information Criterion (BIC). As shown in Table 2, there is not enough
evidence to support that the risks of type 2 diabetes mellitus for those with and without
gestational diabetes are correlated within studies from both the bivariate Beta-binomial
model and the bivariate generalized linear mixed models with three link functions, i.e., the
models with ρ = 0 provide better goodness-of-fit for all four models considered. Note that
the results from different models are very similar here. Based on AICC and BIC, the best
fitted model is a bivariate logit generalized linear mixed effects model with ρ = 0 and
. Based on this model, the population averaged risk of type 2 diabetes mellitus for
those with and without gestational diabetes are estimated to be 0.200 (standard error =
0.031) and 0.025 (standard error = 0.006) respectively. The population averaged risk
difference is estimated to be 0.175 (standard error = 0.031), where the population averaged
risk ratio is estimated to be 7.948 (standard error = 2.167). It is interesting to note that the
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population averaged risk ratio estimates from all models are slightly higher than what
Bellamy et al.21 reported (i.e., 7.43 with 95% confidence interval of 4.79 to 11.51) based on
the random effects model by DerSimonian and Laird.4 The reason might be the fact that an
ad hoc continuity correction was implemented for the studies with zero diabetic events in the
group without gestational diabetes in Bellamy et al.,21 where our models do not.
Because one of the studies has almost all the cases (9502 out of 10859 cases), we did a
sensitivity meta-analysis by excluding that study. The results are presented in Appendix
eTable 1. In summary, it suggests similar conclusions. Specifically, the best fitted model is a
bivariate probit generalized linear mixed effects model with ρ = 0 and , and the
population averaged risk of type 2 diabetes mellitus for those with and without gestational
diabetes are estimated to be .205 (standard error = 0.031) and 0.025 (standard error = 0.007)
respectively. The population averaged risk difference is estimated to be 0.181 (standard
error = 0.032), where the population risk ratio is estimated to be 8.371 (standard error =
2.756).
3.2 Example 2: Meta-analysis of the risk of myocardial infarction with Rosiglitazone
To investigate whether rosiglitazone, a drug for treating type 2 diabetes mellitus,
significantly increases the risk of myocardial infarction (MI) or cardiovascular disease
(CVD)-related death, Nissen and Wolski5 performed a meta-analysis of 48 clinical trials that
satisfied the inclusion criteria for their analysis. Among them, 10 studies have no MI events
and 25 studies have no CVD-related deaths, which were simply excluded by Nissen and
Wolski from their analysis. This meta-analysis data set has been reanalyzed by Shuster et
al.,35 Tian et al.8 and others,36–38 and updated by Dahabreh.39 For the illustration purpose,
we will only focus on the association between rosiglitazone usage and the risk of myocardial
infarction. In summary, 86 out of 16,856 in the rosiglitazone group and 72 out of 12,962 in
the control group had MI event in the 48 clinical trials.
Similar to Section 3.1, we fitted the bivariate Beta-binomial and the bivariate generalized
linear mixed effects models as described in Section 2 on those 48 clinical trials to study the
association between rosiglitazone usage and the risk of MI in type 2 diabetes mellitus
patients. Table 3 presents the parameter estimates and their standard errors, including the
population averaged risk of MI event for those with and without rosiglitazone usage, the
population averaged risk difference and risk ratio, and the goodness of fit measurements
including the finite sample corrected Akaike’s Information Criterion (AICC) and the
Bayesian Information Criterion (BIC). The BGLMM models assuming random effects v1i =
v2i with any of the three link functions provide better model fit than the bivariate Beta-
binomial model with either ρ ≠ 0 or ρ = 0. Based on AICC and BIC, the bivariate logit and
complementary log-log generalized linear mixed effects models with random effects v1i =
v2i provide similar best fit.
It is worthy to mention that for the logit BGLMM model, it seems that the approximation of
, where , slightly overestimate the population
averaged probability of MI for each group. For example, for the logit BGLMM model
assuming random effects v1i = v2i, the estimated population averaged probabilities of MI in
the rosiglitazone treatment and control groups are 0.00627 (standard error = 0.00133) and
0.00480 (standard error = 0.00109) using the approximation of
. While, using the numerical integration by
, the corresponding estimates are 0.00493
(standard error = 0.00140) and 0.00366 (standard error = 0.00114), which are consistent
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with the estimates from other models. However, we notice that the overestimation of the
population averaged probability of MI using the approximation formula of the logit
BGLMM does not seem to have any noticeable effects on the estimation of risk difference or
risk ratio.
4. Discussion
In this article, we discussed bivariate Beta-binomial models derived from Sarmanov family
of bivariate distributions and bivariate generalized linear mixed effects models using a
general link function for meta-analysis of 2 by 2 tables in comparative clinical studies.
Specifically, we have discussed logit, probit and complementary log-log link functions as
special cases. These bivariate random effects models naturally account for the potential
correlation between treatment (or exposure) and control groups within studies. Moreover,
they can be used to make valid inferences using all available data without using ad hoc
continuity corrections for the sparse data scenario. We illustrated the utilization of the
bivariate random effects models in two recent meta-analysis data sets, which emphasizes the
importance of model selection. In particular, based on AICC and BIC, in the example one,
the best fitted model is a bivariate logit generalized linear mixed effects model with ρ = 0
and , which suggests that the study-specific risks of type 2 diabetes mellitus (in logit
scale) for those with and without gestational diabetes are independent and have similar
variations. In the example two, both the bivariate logit and complementary log-log
generalized linear mixed effects models with random effects v1i = v2i provide similar best
fit, which suggests that one can reasonably assume a fixed effect of rosiglitazone on the risk
of myocardial infarction (in logit or complementary log-log scale). Furthermore, we
provided methods to estimate the population averaged risk difference and relative risk. It is
worth to noting that the bivariate Beta-binomial model and the bivariate generalized linear
mixed effects models involves two different distributional assumptions, one would imagine
that their performance would heavily depend on whether the distributional assumptions
approximate the underline data generating mechanism. In particular, the bivariate
generalized linear mixed effects models implies a linear relationship between p1 and p2 on a
transformed scale, and after transforming back to the scale of probability, the relation
between p1 and p2 is no longer linear. The Beta-binomial model implies a linear relationship
between p1 and p2 on the original scale. So which model works better in a particular
application depends on whether the relation between p1 and p2 is linear on the original scale
or on the transformed scale. We suggest that fitting both models and comparing goodness-
of-fit to select the best model to make inference in practice.
Alternative approaches using Bayesian methods can be fitted by free downloadable software
such as WinBUGS, for example, by the Bayesian random effect models as in Warn,
Thompson and Spiegelhalter.40 However, Warn et al. 40 focused on the conditional
treatment effects. Here, we focus on the overall marginal (or population averaged) treatment
effects, as suggested by McCullagh.30, 31 Remark that our parameterization of BGLMM is
slightly different from the random effects models by Smith et al.41 and Warn et al.40
Specifically, Smith et al. 41 considered a Bayesian logit random effects model assuming
logit (p1i)= μi − δi/2, logit (p2i) = μi + δi/2, δi ~ N(δi, σ2), and non-informative priors for the
average event rates, μi s, which are treated as the nuisance parameters. It implicitly restricts
Var[logit(p1i)] = Var[logit(p2i)], i.e., restricting  as in the BGLMM model. Warn et
al.40 assumes that g(p1i) = μi, g(p2i) = μi + δi and δi ~ N(δ, σ2) where g() is a link function,
which implicitly restricts Var[g(p1i)] ≤ Var[g(p2i)], i.e., restricting  in our BGLMM
parameterization. It is worth pointing out that our purpose here is not to demonstrate the
advantage of our approach over a Bayesian approach, because both BGLMM and Bivariate
Beta-binomial models can be fitted using a Bayesian approach. For the general model that
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we considered in equation (2), we do not make any restrictions on the variances of  and
. Furthermore, the bivariate Beta-binomial model and the bivariate generalized linear
mixed models we proposed in this article do not include any study-level or individual level
covariates. It is straightforward to include covariates when using the BGLMM through the
SAS NLMIXED procedure.
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Table 1
Example 1: Data from a Meta-analysis of Studies on Type 2 Diabetes Mellitus after Gestational Diabetes21
Study
Type 2 Diabetes Mellitus with Gestational Diabetes Type 2 Diabetes Mellitus without Gestational Diabetes
# events # observations # events # observations
1 2874 21823 6628 637341
2 71 620 22 868
3 21 68 0 39
4 43 166 150 2242
5 53 295 1 111
6 405 5470 16 783
7 6 70 7 108
8 13 35 8 489
9 7 23 0 11
10 23 435 0 435
11 44 696 0 70
12 21 229 1 61
13 10 28 0 52
14 15 45 1 39
15 105 801 7 431
16 10 15 0 35
17 33 241 0 57
18 14 47 3 47
19 224 615 18 328
20 5 145 0 41
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